Investing in transformative biotech companies

Humanity will always depend on medicines. Continuous innovation in the biotech sector is a given. Bringing better medicines to the market all the time. Aescap is able to select those companies that are developing tomorrow’s medicines. Thereby it can achieve excellent returns over the medium term, without taking large risks.

The Aescap funds invest in highly innovative publicly traded biotech/life sciences companies. The funds are supervised by an AIFM and managed by an experienced investment team with an excellent track record. The members of the investment team significally invest in the funds themselves.  Aescap is heavily involved with the companies it invests in, acting as a private equity investor on the stock market. The name Aescap is derived from ‘Aesculapius’, the Roman god of Medicine, and ‘Capital’.

Sustainable investing

The Aescap funds are classified as article 8 fund, according to the Sustainable Finance Disclosure Regulation (SFDR). In addition to their financial aim to gain value, they promote a social characteristic by investing in companies that develop treatments for diseases with a high unmet medical need.

Investments can have a very positive impact on the quality of life of millions of people.

Update via webcast

We regularly organise information meetings for existing and potential investors. In these meetings we share our investment philosophy as well as methodology. The next meeting takes place on July, 11th.

Meet the investment team

The Aescap investment team, led by portfolio manager Patrick Krol, consists of experienced professionals with different backgrounds in the health care industry. We aim to provide a good financial return to our investors, and in parallel contribute to improving the well-being of millions of people. Our team members invest in the Aescap funds themselves with over 25 million euro.

Interested in investing in Aescap funds?

Subscribe to our newsletter here.



    Latest news

    Home